Irish drugmaker buys Questcor Pharma for $5.6B

04/8/2014 | Reuters · Los Angeles Times (tiered subscription model)

Irish firm Mallinckrodt agreed to pay approximately $5.6 billion to acquire Questcor Pharmaceuticals as part of a strategy to strengthen its presence in the specialty-drugs market. The deal will give Mallinckrodt rights to Questcor's chronic autoimmune and inflammatory drugs including Acthar Gel, which is approved in the U.S. for 19 conditions including multiple sclerosis and is expected to generate $1.9 billion in sales in 2018. The acquisition "will substantially increase the scale, diversification, cash flow and profitability of our business," Mallinckrodt CEO Mark Trudeau said.

View Full Article in:

Reuters · Los Angeles Times (tiered subscription model)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN